← Leaderboards
Ryan J Sullivan
Massachusetts General Hospital
$2,169,747
Attributed
$4,063,745
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $986.9K · FY2016–21$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$4,063,745 · 3
By mechanism
R01$3,787,997 · 2
UH2$275,748 · 1
Top collaborators
- Janice M. Mehnert5 shared
- Arlene H Sharpe4 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Janie M Lee$2,641,472
- Carrie Elizabeth Cunningham$4,319,121
- Richelle C Charles$6,402,547
- Benjamin James Vakoc$7,888,946
- Maged M Henary$3,266,074
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseTargeted TreatmentMelanomaBraf GeneOncogenicResponseTumorInhibitor/AntagonistMalignant NeoplasmsClinical TrialsMouse ModelMitogen-Activated Protein KinasesPathway InteractionsBiopsyMelanoma CellRegimenEffectivenessEnrollmentGenerationsIn VivoMetastatic MelanomaResistanceBiological MarkersCells
Grant awards (11)
Abbreviated targeted therapy to improve anti-PD-1 inhibitor efficacy in melanoma$380,627
R01 · FY2021 · CA · contact PI
Promoting Bim-driven apoptosis through MAPK inhibition: A therapeutic strategy in advanced melanoma$459,563
R01 · FY2020 · CA · contact PI
Abbreviated targeted therapy to improve anti-PD-1 inhibitor efficacy in melanoma$380,517
R01 · FY2020 · CA · contact PI
Promoting Bim-driven apoptosis through MAPK inhibition: A therapeutic strategy in advanced melanoma$441,168
R01 · FY2019 · CA · contact PI
Abbreviated targeted therapy to improve anti-PD-1 inhibitor efficacy in melanoma$370,800
R01 · FY2019 · CA · contact PI
Clinical development of a blood based assay that detects the BRAF V600E mutation in melanoma and thyroid cancer patients$135,613
UH2 · FY2019 · CA · contact PI
Promoting Bim-driven apoptosis through MAPK inhibition: A therapeutic strategy in advanced melanoma$448,463
R01 · FY2018 · CA · contact PI
Abbreviated targeted therapy to improve anti-PD-1 inhibitor efficacy in melanoma$398,271
R01 · FY2018 · CA · contact PI
Clinical development of a blood based assay that detects the BRAF V600E mutation in melanoma and thyroid cancer patients$140,135
UH2 · FY2018 · CA · contact PI
Promoting Bim-driven apoptosis through MAPK inhibition: A therapeutic strategy in advanced melanoma$495,652
R01 · FY2017 · CA · contact PI
Promoting Bim-driven apoptosis through MAPK inhibition: A therapeutic strategy in advanced melanoma$412,936
R01 · FY2016 · CA · contact PI